NOV 09, 2017 10:30 AM PST

Fast Phenotypic Antibiotic Susceptibility Testing of Positive Blood Cultures

SPONSORED BY: Accelerate Diagnostics
C.E. CREDITS: P.A.C.E. CE | Florida CE
Speakers
  • Professor of Pathology and Laboratory Medicine, Scientific Director and Microbiology, Cedars-Sinai Medical Center
    Biography
      Dr. Morgan has over 30 years of laboratory experience first as a bench technologist and then laboratory director. Her professional focus has been antimicrobial stewardship, Clostridium difficile diagnostic strategies and infection control measures, and application of molecular methods to the microbiology laboratory. These interests have led to over 100 abstracts and publications.

      Dr. Morgan earned her BS in Medical Technology at the University of Oklahoma, and her PhD in Medical Microbiology and Immunology at the University of Oklahoma Health Sciences Campus. She obtained a Fellowship in Clinical Microbiology at the Mayo Clinic (Rochester, MN). She is certified by the American Board of Medical Microbiology.

      She has been twice awarded the Golden Apple Award for teaching Medical students, Pathology residents and Infectious Disease Fellows at Cedars-Sinai medical center. She has spoken at numerous regional and national meetings, presented numerous national webinars, and she is the past president of her local ASM chapter (SCASM), and hosts a microbiology blog on the internet for the review of microbiology, "Microbes with Dr. Morgan".

      Dr. Morgan is a Professor in Pathology and Laboratory Medicine and Director of the Microbiology Laboratory at Cedars-Sinai Medical Center, where she has worked for 34 years.

    Abstract:

    The role of the microbiology laboratory in the processing of positive patient blood cultures has become more complicated with the increasing demand for rapid information to assist in the management of sepsis.  Many laboratories have turned to using molecular systems that report identification and resistant marker results that supply actionable information but no susceptibility data.  These systems have proven over time to be useful with the management of Gram positive bloodstream infections but vary in the ability to properly guide therapy choices for Gram negative bacteremia.   In our institution, phenotypic antimicrobial susceptibility results are often necessary for optimization of therapy. This is particularly true due to emerging resistance mechanisms in Gram negative bacilli, such as AmpC and porin alterations.  The Accelerate Pheno™ system is a truly unique and divergent technology that has the potential to produce final susceptibility results directly from a positive blood culture within 7 hours.  This is a reduction in time to results from conventional susceptibility methods of 2-3 days.   The Accelerate Diagnostics system was FDA cleared in February of 2017.  Clinical trial and scientific presentations have shown the identification and MIC susceptibility results to be reliable and can be used to improve patient care.  Rapid final MIC results provide invaluable information to a stewardship program to rapidly optimize the therapy of sepsis.


    Show Resources
    Show Resources